Psyched Wellness Receives DTC EligibilityCybin Advances IND-Enabling Studies of Two Psychedelic Molecules, CYB003 and CYB004 for Investigational New Drug ApplicaRritual Appoints Sarton Molnar-Fenton, Vice President Sales USATryp Therapeutics Announces Listing on OTCQB and DTC EligibilityPure Extracts Dual Vertical Approach Incorporating Cannabis and Psychedelic Compounds Is Starting To Pay OffTryp Therapeutics Appoints Greg McKee as Chief Executive OfficerPsyence Group and Pure Extracts Sign JV Letter of Intent for the Extraction of Psilocybin from Psychedelic Mushrooms andCybin Announces Senior Management Changes to Lead Buildout of Development and Clinical Capabilities in the United StatesPsyched Wellness Initiates Study on AME-1 Extract for Gut HealthRritual Superfoods to Launch Product Line in Rite Aid Stores – NationwideMushroomStocks.com Deep Dive: Tryp Therapeutics (CSE:TRYP)Cybin Signs Drug Development Agreement with Catalent for its Fast-Dissolve Formulation of Novel, Deuterated Tryptamine (Field Trip Has A Warchest Of Cash To Propel R&D and M&A Moving ForwardCybin Inc. Is Rapidly Progressing Its Drug Development Program With Plenty On The HorizonPure Extracts Orders Cutting Edge Vitalis Cosolvent Injection SystemTryp Therapeutics Announces Provisional Patent Filing For Improved Administration of PsychedelicsCybin Progresses Two Psychedelic Investigational New Drug (“IND”) Candidates and Announces Completion of Its 20th PrRritual Announces Successful Completion of Second Full Scale Manufacturing Run and Commencement of Third Full Scale ManuNuminus Wellness Is Taking Strides To Advance Its R&D Business UnitRritual Announces Successful Launch of US Facing E-Commerce Website and Provides Corporate Update

Join the top platform for cannabis stock analysis.

Premium Newsletter & Content Feed

A daily stream of market moving news, company announcements and earnings announcements keeps your finger on the pulse of the market.

Priority Access to Our Analysts

Have an urgent question on a stock, company, or trade? As a premium member, you have direct, priority access to our team.

Member’s Dashboard

Everything you need in one convenient, sleek dashboard. Access your premium news, market data, exclusive Mushroomstocks reports, and more.

What Members are Saying:

  • “In the crazy world of cannabis stocks, I’ve found Techincal420’s advice knowledge and invaluable. Techincal420’s team does a great job researching companies which helps me concentrate on the right companies. ” PAUL
  • “I read about technical 420 a couple months ago on a CNBC article… I was thrilled about Michael Berger’s idea of covering this seed-stage market since day one. Personally, I think the article undersold the value that Michael provides his subscribers. Michael is able to find value in an opaque market and rely that information in a way that is easy to understand and act on. If you want to invest in cannabis stocks, Mushroomstocks is the place to go!” ERALDO
  • “I want to thank Michael Berger for creating this resource. Similarly, I asked my Raymond James investment advisor about resources for investing in the Cannabis industry. I was given this website, among others. Out of all the resources I was given, Mushroomstocks without a doubt provides the most thorough and non-biased information on marijuana stocks and the cannabis industry. ” KAI
  • “Michael is a wiz when it comes to the stock market. I came to Mushroomstocks without any investment experience and Michael essentially tutored me and explained how everything works and why it works in the fashion it does. When it comes to the marijuana industry there is no one better. His cutting edge approach to this promising, yet opaque market is second to none. I would unquestionably recommend him to anyone who wants to learn about the marijuana stock industry.” NIMZJAB

The psychedelics sector is starting to take off as smart money begins to position itself across the industry.

Stay updated with all latest updates,upcoming events & much more.
Subscribe
SUBSCRIBE NOW
close-link